

Date: 13.08.2024

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051

NSE SYMBOL: MKPL

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Tuesday, August 13, 2024, *inter alia*, considered and approved:

- (i) the Un-Audited Financial Results for the quarter ended June 30, 2024 along with the Limited Review Report thereon by the Statutory Auditors of the Company.
 - A copy of the Un-Audited Financial Results along with Limited Review Report of the Auditors is attached herewith as Annexures.
- (ii) The appointment of M/s. J.P. Jagdev & Co., Company Secretaries, as Secretarial Auditor of the Company to conduct the Secretarial Audit for the financial year 2023-24 and to issue the Secretarial Audit Report thereon;

The disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is attached as Annexure-A.

The meeting of the Board of Directors commenced at 03:00 p.m. and concluded at 03:30 p.m. You are requested to take the same on your record.

Thanking You,

Yours Sincerely, FOR M K PROTEINS LIMITED

Neha Aggarwal Company Secretary cum Compliance Officer

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T: 0171-2679358 I W: www.mkproteins.in I E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01021



Anexure-1

DETAILS UNDER REGULATION 30 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

S. No.	PARTICULARS	DETAILS
1.	Reason for change viz. appointment, resignation, removal, or otherwise	Appointment: To comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of appointment/cessation & term of appointment	Date: August 13, 2024. M/s. J.P. Jagdev & Co., Company Secretaries is appointed as Secretarial Auditor of the Company for the F.Y 2023-24
3.	Brief Profile (in case of appointment)	Name of Secretarial Auditor: M/s. J.P. Jagdev & Co, Company Secretaries Email id: jpjncoin@gmail.com Office Address: 22-A, Kanshi Nager, Model Town, Ambala City-134003 Field of Experience: Mr. Jai Prakash Jagdev, is a Company Secretary (M. No. 2469 & COP No. 2056), based in Ambala. He has vast experience in the field of Company Law, Secretarial Work, Due Diligence, SEBI Regulations etc.
4.	Disclosure of relationships between directors (in case of appointment of a director).	NA

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024

(Rs. In Lacs)

		Q	QUARTER ENDED			YEAR ENDED	
		30-06-2024 (UNAUDITED)	31-03-2024 (AUDITED)	30-06-2023 (UNAUDITED)	31-03-2024 (AUDITED)	31-03-2023 (AUDITED)	
1.	Revenue						
a)	Revenue from Operation (Net)	5733.30	8687.29	7619.51	24557.11	31486.00	
b)	Other Income	0.00	41.04	0.00	44.66	55.35	
	Sub-Total "1"	5733.30	8728.33	7619.51	24601.77	31541.35	
2.	Expenditure						
a)	Cost of Material Consumed	2559.25	11144.47	3192.89	20571.80	25574.42	
h)	Purchase of Stock-in-Trade	407.96	358.70	1457.11	3294.36	4912.19	
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	21 5 6.91	(3985.10)	2107.70	(2223.11)	(1967.95)	
d)	Employees Benefits Expenses	65.78	79.26	68.72	278.80	177.06	
e)	Manufacturing, Operating and Other Expenses	169.46	247.67	393.23	973.61	1080.47	
f)	Finance Costs	32.82	39.77	52.37	106.49	184.16	
g)		7.41	17.76	11.61	52.85	82.02	
	Sub-Total "2"	5399.59	7902.53	7283.63	23054.80	30042.37	
3	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1-2]	333.71	825.80	335.88	1546.97	1498.98	
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	
5	Profit/(Loss) before Extraordinary items and Tax [3-4]	333.71	825.80	335.88	1546.97	1498.98	
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	
7	Profit/(Loss) before Tax [5-6]	333.71	825.80	335.88	1546.97	1498.98	
8	Tax Expenses						
a)	Provision for Current Tax	84.49	236.15	86.37	417.73	399.52	
b)	Provision for Deferred Tax Liability/(Adjustment)	1.09	6.67	0.46	8.05	6.00	
c)	Prior Year Taxes	0.00	0.00	0.00	0.00	0.00	
	Sub-Total "8"	85.58	242.82	86.83	425.78	405.52	
9	Profit/(Loss) for the Period from continuing operations [7-8]	248.13	582.98	249.05	1121.19	1093.46	
10	Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00	
	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00	
12	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00	
13	Profit/(Loss) for the period [9 + 12]	248.13	582.98	249.05	1121.19	1093.46	
14	Other Comprehensive Income net of taxes			7 /			
a)	(i) Amount of items that will not be reclassified to profit and loss	0.00	(0.55)	0.00	(0.55)	0.79	
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	(0.14)	0.00	(0.14)	0.20	
	(i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	
	Sub- Total "14"	0.00	(0.41)	0.00	(0.41)	0.59	
15	Total comprehensive Income for the Period [13 + 14]	248.13	582.57	249.05	1120.78	1094.05	



16	Earnings per share (refer Note 7)	7. 125154-10.103				
	Earnings per Equity Share for continuing operations					
	Basic earnings/(Loss) per share from continuing operations	0.07	0.16	1.99	0.30	8.74
	Diluted earning/(Loss) per share from continuing operations	0.07	0.16	1.99	0.30	8.74
b)	Earnings per Equity Share for discontinuing operations					
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share					
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.07	0.16	1.99	0.30	8.74
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.07	0.16	1.99	0.30	8.74
17	Details of Equity Share Capital					
	Paid-up Equity Share Capital	3753.72	3753.72	1251.24	3753.72	1251.24
	Face value of Equity Share Capital	1	1	10	1	10
18	Other Equity [Reserves]	-			2353.84	3735.19

Note:

- 1. The above mentioned audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th August, 2024.
- 2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
- The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations & Disclosure Requirements, 2015).
- 4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.

Place: Ambala

Dated: 13-08-2024

For and on behalf of the board

(Parmod Kumar) Managing Director DIN: 00126965





a 011 - 47082855 Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

<u>Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant</u>
<u>to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015</u>

To, The Board of Directors, M. K. Proteins Limited

- 1. We have audited the accompanying statement of unaudited quarterly standalone financial results of M. K. Proteins Limited ("the Company") for the quarter ended June 30, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.
- 2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular No. CIR/CFD/FAC/62/2076 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies [Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi

Date: 13th August 2024

For KRA & Co., Chartered Accountants Firm Registration No. 020266N

(PARTNER) Membership No.: 503150 UDIN: 24503150BKAMAQ7638

GOYAL